Vitiligo treatment advertising: FDA and FTC rules

Vitiligo care has changed in the past few years, and practice marketing has followed. Pages now promise “restore your natural skin color,” “FDA-approved vitiligo cure,” “excimer laser clears white patches in weeks” and “safe for kids.” Most of that wording runs ahead of what FDA’s records and the federal health agencies actually say.

This guide covers what NIH says about vitiligo, what the one prescription drug label with a vitiligo indication says about who it is for and how well it worked, what the 510(k) clearances for 308 nm excimer devices say, and how FDA and FTC rules apply to cure claims, age wording, before-and-after photos and packages. We do not name any drug, device, brand or company. For general dermatology marketing, see our guide to dermatology practice marketing. Light treatment for psoriasis and eczema is covered in our guide to psoriasis and eczema clinic marketing. For the opposite pigment problem, see our guide to melasma treatment marketing.

This is general information, not legal or medical advice. Sources cited were checked on November 1, 2026: NIAMS’s health topic page on vitiligo (last reviewed October 2022); prescription drug labeling with a vitiligo indication as listed in openFDA (drug label data last updated October 30, 2026; the label we read is dated June 30, 2026); FDA device classification and 510(k) data read through openFDA (device data last updated October 19, 2026) and the 510(k) indications statements for K193478 (January 14, 2020) and K242977 (February 6, 2025); 21 CFR 878.4630, 878.4810, 807.97 and 202.1 and 16 CFR 255.2 and 233.1 in the eCFR version as of October 29, 2026; 21 USC 352 and 396 and 15 USC 45, 52 and 55 in the Cornell LII text of the U.S. Code; FDA’s page on unapproved use of approved drugs; and the FTC Health Products Compliance Guidance (December 2022). We did not review the medical literature on vitiligo or ad platform policies.

The short version

No cure. NIAMS says there is no cure for vitiligo, while treatments can stop its progression and reverse its effects. “Cure” and “permanent” wording does not fit.
One approved prescription drug label names vitiligo. A topical cream for nonsegmental vitiligo in patients 12 and older, on up to 10% of body surface area, with a boxed warning. In its trials, about 3 in 10 patients reached at least 75% improvement on the face at 24 weeks.
Excimer devices are cleared, not approved. Several 308 nm excimer devices have 510(k) clearances that list vitiligo. A clearance does not denote FDA approval (21 CFR 807.97).
Ages and areas matter. The drug’s safety and effectiveness for vitiligo are not established under age 12. “Safe for kids” is a claim you would need to support.
Photos carry claims. A before-and-after with full repigmentation is likely to be read as typical unless you say what patients generally get (16 CFR 255.2).

What NIH says about vitiligo

NIAMS, the NIH institute for skin diseases, describes vitiligo as a chronic autoimmune disorder that causes patches of skin to lose pigment when melanocytes, the cells that make pigment, are attacked and destroyed. It separates the common form, in which patches usually appear on both sides of the body, from the less common segmental subtype, which affects one segment or side of the body. That distinction matters for marketing, because the approved drug label covers nonsegmental vitiligo only.

NIAMS also says there is no cure for vitiligo, though treatments can be very effective at stopping its progression and reversing its effects, and that people with vitiligo can develop low self-esteem or a poor self-image from concerns about appearance (page last reviewed October 2022). Two practical points follow. “Cure” claims contradict the federal health agency’s own summary, and ads that lean on shame or fear about appearance reach an audience NIH flags as vulnerable to exactly that.

The approved topical drug: what the label says

A search of openFDA’s drug labeling data (last updated October 30, 2026) for vitiligo in the indications section returned one prescription drug label with an approved application number: a topical Janus kinase (JAK) inhibitor cream, label dated June 30, 2026. It is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. The details a practice page should not contradict:

Area limit. Applied twice daily to affected areas of up to 10% of body surface area, with a weekly tube limit.
Time. The label says satisfactory response may require more than 24 weeks of treatment, and that a patient who does not find the repigmentation meaningful by 24 weeks should be re-evaluated.
Combination limit. Use with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.
Boxed warning. The label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis, written with data from oral JAK inhibitors.
Age. Safety and effectiveness for nonsegmental vitiligo have not been established in patients younger than 12.

The trial results are modest and specific. In two 24-week trials (674 patients total, phototherapy not permitted, average time since diagnosis 14.8 years), 29.9% of patients on the cream in each trial reached at least 75% improvement in the facial vitiligo score, compared with 7.5% and 12.9% on the vehicle cream. At least 90% facial improvement was reached by 15.5% and 15.4% on the cream. Patients had to have facial involvement, and 82% of trial participants were white, with Fitzpatrick skin types V and VI making up 9%.

For an ad, that means “clear skin in weeks” and “works for everyone” do not match the label. Most patients in the trials did not reach the main goal at 24 weeks, and the label tells prescribers to re-evaluate patients at that point.

openFDA’s label search also returned labels for homeopathic and over-the-counter skin products that mention vitiligo. Those are labels their makers submitted, without an approved application number. Being listed is not FDA approval, so a practice should not describe such a product as an FDA-approved vitiligo treatment.

Naming the drug, the boxed warning and off-label use

FDA’s prescription drug ad rule requires a manufacturer’s ad to give a fair balance of risk and benefit and bars it from suggesting uses outside the approved labeling (21 CFR 202.1(e)(4)(i)(a), (e)(5)(ii)), a duty written for the manufacturer, packer or distributor (21 USC 352(n)). We found no FDA rule that applies it directly to a practice’s own service ads. FTC law does apply: under 15 USC 55(a)(1), whether an ad is misleading depends partly on what it fails to reveal, and a page that names a drug with a boxed warning while saying only “safe, steroid-free and gentle” leaves out the facts a reader needs.

FDA’s page on unapproved uses says a provider may generally prescribe an approved drug for an unapproved use when they judge it medically appropriate. Prescribing is not advertising. A page that promotes the cream for segmental vitiligo, for children under 12 or for areas beyond the label’s limit as if those uses were FDA-backed would be presenting a use FDA did not approve. Our guide to advertising a prescription treatment covers drug naming, risk wording and off-label claims in detail.

Excimer lasers and lamps: cleared, not approved

Office light treatment for vitiligo usually means 308 nm excimer devices. In FDA’s records they sit under two product codes:

FTC, ultraviolet dermatological light, 21 CFR 878.4630. The regulation identifies an ultraviolet lamp for dermatologic disorders, Class II. A 510(k) cleared on February 6, 2025 (K242977) lists the indication as treatment of psoriasis and vitiligo, on intact skin only.
GEX, powered laser surgical instrument, 21 CFR 878.4810. A general laser category, Class II. A 510(k) cleared on January 14, 2020 (K193478) lists UVB phototherapy for psoriasis, vitiligo, atopic dermatitis and leukoderma, for prescription use.

A clearance means FDA found the device substantially equivalent to one already on the market for the stated indication. 21 CFR 807.97 says a 510(k) clearance does not in any way denote official approval of a device, and that a representation creating that impression is misleading and misbranding. So “FDA-approved excimer laser” is the wrong word, while “an FDA-cleared 308 nm excimer device” can be accurate if you have checked your own device’s 510(k) number and its indications.

Under 21 USC 396, a clinician may use a legally marketed device as they judge best for a patient, but the law says this “shall not change any existing prohibition on the promotion of unapproved uses.” If your device’s clearance does not list vitiligo, do not market it for vitiligo as if FDA had reviewed that use. The clearance also says nothing about how many sessions it takes or how much color returns. Those are claims that need their own evidence. See our guide to medical device marketing claims.

Cure, permanence and “restore your color” claims

Section 5 of the FTC Act declares unfair or deceptive acts or practices unlawful (15 USC 45(a)), and section 12 makes it unlawful to disseminate a false advertisement to induce the purchase of drugs, devices or services (15 USC 52). The FTC Health Products Compliance Guidance says health claims need competent and reliable scientific evidence, and the FTC reads an ad for its net impression.

“Cure” and “gone for good.” NIAMS says there is no cure. These words are hard to support.
“Restore your natural color.” Implies full repigmentation. The drug trials measured partial improvement, and most patients did not reach 75% facial improvement at 24 weeks.
“Results in weeks.” The drug label points to 24 weeks or more. Any time claim for light sessions needs evidence for that protocol.
“Works on all skin types.” The drug trials enrolled few patients with the darkest skin types. A broad claim needs evidence that covers those patients.
“Stops vitiligo from spreading.” A disease-progression claim. State it only as far as your evidence goes, for the treatment you actually offer.

Wording that stays closer to the record: “We offer prescription and in-office light treatment for vitiligo. Many patients see some color return over months, results vary, and no treatment cures vitiligo. We will talk through options, time frames and risks at your visit.”

Age wording and pediatric patients

Vitiligo often starts young; NIAMS notes that for many people the white patches begin to appear before age 20 and can start in early childhood. Pediatric pages need care:

Do not present the approved cream as a children’s treatment below age 12; the label says safety and effectiveness have not been established there.
“Safe for kids” and “gentle enough for children” are safety claims. They need support for the specific treatment and age.
Speak to parents, not children, and avoid appearance-shaming language aimed at teens. See our guide to pediatric practice marketing.

Before-and-after photos and patient stories

Vitiligo photos are powerful, which is why they need the most care. Under 16 CFR 255.2(a), an advertiser must have substantiation for what a consumer endorsement conveys, as if it made the claim itself. Under 16 CFR 255.2(b), an endorsement about a central attribute is likely to be read as showing typical results unless the ad clearly and conspicuously discloses the generally expected results. A gallery of near-complete repigmentation, next to trial results where most patients did not reach 75% facial improvement at 24 weeks, needs that disclosure.

Show the treatment used, the number of weeks or sessions, and that results vary.
Use the same lighting, angle and camera for before and after, so the comparison is fair.
Do not retouch or filter the treated area.
Include patients whose results were partial, not only the best cases.
Get written authorization before using any patient photo. Our guide to patient photo consent for marketing covers the process, and patient testimonials and before-and-after photos covers the FTC side.

Packages, prices and insurance wording

Session packages. “20 excimer sessions” is fine as a price unit. “20 sessions to clear skin” is an outcome promise.
Former prices. “Was $1,500, now $900” needs a former price you actually offered in good faith for a reasonably substantial period (16 CFR 233.1(a)).
Coverage. “Covered by insurance” is a factual claim. Say it only for plans you have confirmed, and say that coverage depends on the plan.
Cosmetic camouflage and depigmentation. If you offer them, describe them plainly; they are different services from repigmentation.

See our guide to advertising cash prices.

An example (made up)

This illustration is invented. A practice posts: “FDA-approved vitiligo cure! Our new cream and excimer laser restore your natural color in 8 weeks. Safe for all ages and all skin types. 20 sessions, was $3,000, now $1,200.”

Fixes: “cure” comes off; NIAMS says there is no cure. “FDA-approved” for the laser becomes “FDA-cleared,” and only if the device’s 510(k) lists vitiligo (21 CFR 807.97). “Restore your natural color in 8 weeks” comes off; the drug label points to 24 weeks or more and partial results for most patients. “Safe for all ages” comes off; the cream is not established under 12. “All skin types” comes off without evidence that covers them. The former price stays only if patients actually paid $3,000 for a reasonable period. A version that works: “Prescription cream and in-office 308 nm excimer light for vitiligo, for patients 12 and up. Many see some color return over several months. Results vary and vitiligo has no cure. Book a visit to talk through options and risks.”

Checklist

No “cure,” “permanent” or “restore your natural color” wording (NIAMS; 15 USC 45, 52; FTC guidance).
The approved cream described within its label: nonsegmental vitiligo, age 12 and up, up to 10% body surface area, boxed warning not hidden (openFDA label June 30, 2026; 15 USC 55(a)(1)).
No promotion of uses outside the label as if FDA approved them (21 CFR 202.1; FDA unapproved use page).
Excimer devices called cleared, not approved, with your device’s 510(k) indications checked (21 CFR 807.97; 21 USC 396).
Time frames, skin type and age claims backed by evidence or removed.
Photos show treatment, time and typical results, with written authorization (16 CFR 255.2).
Packages, former prices and insurance wording are real and clear (16 CFR 233.1).

How we help

We build dermatology service pages with claims checked against the sources above: website design, healthcare SEO for searches like “vitiligo treatment near me,” and lead generation campaigns that describe vitiligo care without cure, approval or age overclaims. We do not decide which treatment fits a patient, we do not give legal opinions, and we are not a law firm. Related guides: hyperhidrosis treatment marketing and skin cancer clinic marketing.

Is there an FDA-approved treatment for vitiligo?

Yes, one. openFDA’s labeling data (last updated October 30, 2026) lists one prescription drug label with a vitiligo indication: a topical JAK inhibitor cream for nonsegmental vitiligo in patients 12 and older, on up to 10% of body surface area, with a boxed warning. Excimer devices for vitiligo are 510(k) cleared, not approved.

Can we say our excimer laser is FDA approved for vitiligo?

No. Excimer devices reach the market through 510(k) clearance, and 21 CFR 807.97 says a clearance does not denote official approval. Say “FDA-cleared” only after checking that your device’s 510(k) indications list vitiligo.

Can we advertise vitiligo treatment as a cure?

We would not. NIAMS says there is no cure for vitiligo, though treatments can stop its progression and reverse its effects. A cure claim needs competent and reliable scientific evidence under FTC rules (15 USC 45, 52).

Can we market the vitiligo cream for young children?

Not as an FDA-backed use. The label says safety and effectiveness for nonsegmental vitiligo have not been established under age 12. A clinician may prescribe off label, but promoting that use is different.

Do before-and-after vitiligo photos need a disclaimer?

If a photo shows a result that is better than what patients generally get, the ad should clearly disclose the generally expected results (16 CFR 255.2(b)). In the drug’s trials, most patients did not reach 75% facial improvement at 24 weeks.

Vitiligo treatment marketing: the approved cream, excimer light, photos and age wording